

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/395, G01N 33/53, 33/68 // C07K 14/705, 16/28		(11) International Publication Number: WO 98/25647
A1		(43) International Publication Date: 18 June 1998 (18.06.98)
(21) International Application Number: PCT/US97/22743		(81) Designated States: AU, CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: 9 December 1997 (09.12.97)		
(30) Priority Data: 60/032,963 13 December 1996 (13.12.96) US 08/954,279 20 October 1997 (20.10.97) US		
(71) Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER [US/US]; 330 Brookline Avenue, Boston, MA 02215 (US).		
(72) Inventors: FLEMING, Tony; 219 Tremont Street, Newton, MA 02158 (US). KINET, Jean-Pierre; Three Hunt Road, Lexington, MA 02173 (US).		
(74) Agents: GRANAHAN, Patricia et al.; Hamilton, Brook, Smith & Reynolds, P.C., Two Militia Drive, Lexington, MA 02173 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: CALCIUM-INDEPENDENT MODULATION BY CD81 OF RECEPTOR SIGNALLING		
(57) Abstract Calcium-independent CD81 inhibition of IgE-mediated degranulation in mast cells, particularly through the FcγRIII and FcεRI receptors, is described, as well as methods of inhibiting allergic processes.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

CALCIUM-INDEPENDENT MODULATION BY CD81 OF RECEPTOR SIGNALLING

BACKGROUND OF THE INVENTION

In the past two decades, tremendous advances have been made in understanding the molecular mechanisms used by various types of cell surface receptors to transduce signals. Nearly all of these advances have come from the study of model systems where a receptor "activates" cells to generate a well-defined response. As knowledge about activating model systems has increased, it has become clear that there are many situations in which the activating signal sent from one receptor is modulated as the direct result of a negative or inhibitory signal sent by another cell surface receptor. While the study of this type of signaling is generally in its infancy, several recent studies have begun to shed light on the molecular mechanisms which underlie receptor-mediated inhibitory signals in immunologic systems. Given the tendency of nature to utilize signaling functions modularly in a variety of signaling pathways, the paradigms outlined by these systems may have implications for the study of inhibitory or deactivating signals in non-immunologic situations as well. In addition, the study of these signals may add new dimensions to the understanding of other widely utilized signaling pathways.

SUMMARY OF THE INVENTION

As described herein, monoclonal antibodies (mAbs) have been isolated which inhibit FcεRI-induced mast cell degranulation. Through protein isolation, peptide sequencing, cloning, and gene expression, CD81 has been identified as a novel inhibitory receptor for FcεRI and FcγRIII. Anti-CD81 mAbs also inhibited passive cutaneous

-2-

anaphylaxis (PCA) reactions, a model of IgE-dependent, mast cell activation *in vivo*.

The invention pertains to a method of inhibiting cell surface receptor-mediated signaling comprising contacting a cell with an agent which induces CD81-mediated signal transduction. In a particular embodiment, the cell surface receptor is selected from the group consisting of FcεRI and FcγRIII. In one embodiment, the method is a calcium independent method.

10 The invention also relates to a method of inhibiting degranulation comprising contacting a cell with an agent which induces CD81-mediated signal transduction. In one embodiment, degranulation is mediated by the FcεRI receptor. In another embodiment, the method is a calcium
15 independent method.

The invention further relates to a calcium independent method of inhibiting cell surface receptor mediated signaling in a mammal, such as a human, comprising administering to the mammal an effective amount of an agent
20 which induces CD81-mediated signal transduction. In one embodiment, the cell surface receptor is selected from the group consisting of FcεRI and FcγRIII.

The invention also pertains to a method, e.g., a calcium independent method, of inhibiting degranulation induced by a cell surface receptor-mediated signal in a
25 mammal, such as a human, comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction.

The invention further pertains to a method of treating
30 (e.g., preventing or reducing the severity of) an allergic condition in a mammal, such as a human, comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction. In

- 3 -

particular embodiments, the allergic condition is asthma, hay fever or atopic eczema.

The invention also relates to a calcium independent method of enhancing cell surface receptor-mediated signaling, e.g., FcεRI-mediated signaling and FcγRIII-mediated signaling, comprising contacting a cell with an agent which inhibits CD81-mediated signal transduction.

The invention also pertains to a calcium-independent method of enhancing degranulation comprising contacting a cell with an agent which inhibits CD81-mediated signal transduction. For example, degranulation can be mediated by the FcεRI receptor. The invention also relates to a calcium independent method of enhancing cell surface receptor-mediated signaling in a mammal comprising administering to the mammal an effective amount of an agent which inhibits CD81-mediated signal transduction.

The invention further relates to an assay for identifying agents which alter CD81-mediated signal transduction, comprising combining a cell bearing CD81 with an agent to be tested, under conditions suitable for CD81-mediated signal transduction, and determining the level of CD81-mediated signal transduction. If the level of CD81-mediated signal transduction is altered relative to a control, the agent alters CD81-mediated signal transduction. In a particular embodiment, the agent is one which enhances or induces CD81-mediated signal transduction.

The invention also relates to an assay for identifying agents which alter calcium independent CD81-mediated regulation of cell surface receptor signaling, comprising combining a cell bearing CD81 and an appropriate cell surface receptor with an agent which alters CD81-mediated signal transduction under conditions suitable for signal

-6-

transduction by CD81 and the cell surface receptor, and determining the level of cell surface receptor signaling. If the level of cell surface receptor signaling is altered relative to a control, the agent alters calcium independent CD81-mediated regulation of cell surface receptor signaling.

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A-1C illustrate representative immunologic inhibitory signaling systems. Solid dots on sIg, FcγRIII and TCR indicate tyrosine phosphorylation of activating motifs in the cytoplasmic tails of each activating receptor (Figures 1A-1C, respectively). Solid dots on FcγRIIB, KIR and CTLA-4 indicate tyrosine phosphorylation of inhibitory motifs in the cytoplasmic tails of each inhibitory receptor (Figures 1A-1C, respectively). Figure 1A illustrates the surface immunoglobulin receptor (sIg) complex and FcγRIIB system. FcγRIIB provides a negative feedback signal for soluble immunoglobulin production. Figure 1B illustrates the negative regulation of cytolytic immune cells by killer cell inhibitory receptors (KIR). Figure 1C illustrates the negative regulation of T-cell receptor-mediated activation signals by CTLA-4.

Figure 2 illustrates the schematic structures of SHP1, SHP2 and SHIP.

Figure 3 illustrates the proposed SHP and SHIP inhibitory signaling mechanisms. Solid dots on sIg indicate tyrosine phosphorylation of activating motifs in the cytoplasmic tails of each activating receptor. Solid dots indicate tyrosine phosphorylation of inhibitory motifs in the cytoplasmic tails of each inhibitory receptor.

Figure 4 illustrates 5D1 mAb inhibition of FcεRI-mediated degranulation in RBL-2H3 cells.

Figure 5 illustrates Ly-C peptide 1A12 sequence and alignment with mouse and human CD81.

Figures 6A-6B are the results of FACS analysis illustrating expression of rat CD81 in CHO and NIH-3T3 cells. Figure 6A shows stable expression of rat CD81 in CHO cells stained with 1A12 mAb. Figure 6B shows transient expression of rat CD81 in NIH-3T3 cells infected with M.O.I.=5 of rat CD81 recombinant vaccinia virus and incubated for 6 hours prior to staining with 5D1 mAb.

Figures 7A-7D are graphs of the effect of preincubation of purified mAb 5D1 on FcεRI-mediated degranulation in RBL-2H3 cells. Data shown indicate the results of degranulation of IgE-saturated RBL-2H3 cells after incubation with buffer (filled circles) or purified 5D1 mAb at 2.5 ng (filled squares), 25 ng (filled triangles), or 250 ng (filled inverted triangles) (Figures 7A, 7C, 7D) or with 100 ng (7B) of 5D1 mAb per 10⁶ cells prior to triggering with the indicated concentrations of DNP-HSA (Figure 7A), 50 ng/ml DNP-HSA (Figures 7C and 7D) or with PMA and ionomycin (Figure 7B). Data are expressed as mean dpm ± standard deviation or as percentages of control (no antibody) mean dpm. Statistical significance versus untreated controls was determined using an unpaired Student's t-test: *, p<0.05; **, p<0.01; ***, p<0.001 for Figure 8A. All data points in Figures 8B and 8D were found to be significantly different from controls (p<0.02) with the exception of the 5 minute preincubation time point with 2.5 ng mAb 5D1 (Figure 8C, p=0.067).

Figure 8 shows expression of rat CD81 in mouse mast cell line C1.MC/C57.1 by FACS staining with 5D1 and 1A12 mAbs.

Figures 9A-9C are graphs showing that CD81 mAbs fail to inhibit FcεRI-induced tyrosine phosphorylation, calcium mobilization, and leukotriene synthesis. Figure 9A shows

-6-

the effect of anti-CD81 on calcium mobilization of fura-2-loaded RBL-2H3 cells triggered through FcεRI as measured by confocal microscopy. Fluo-3 fluorescence per ml ³H measurements were normalized by dividing the average

- 5 fluorescence intensity (F) occurring during the course of the experiment to the average fluorescence intensity at the beginning of the experiment (F_0) and expressed as F/F_0 . Traces are shown of 10 individual cell (thin lines) together with mean values for these cells (thick lines) and
- 10 represent typical results obtained from five separate experiments. Figure 9B shows ³H-serotonin release from RBL-2H3 cells prepared as in confocal microscopy measurements except that 3 μCi/ml ³H-serotonin was added to cultures. Figure 9C shows LTC₄ measurements from 10⁶ anti-
- 15 DNP IgE saturated RBL-2H3 treated with 1 μg 5D1 (open squares) or buffer (open circles) prior to triggering with 30 ng/ml DNP-HSA for the indicated periods of time.

- Figure 10A-10B are graphs showing inhibition of passive cutaneous anaphylaxis in Wistar rats by anti-CD81.
- 20 Male Wistar rats were injected with (Figure 10A) 25 ng DNP-specific IgE mixed with 50 μg anti-CD81 mAb 5D1 (mouse IgG1) or control mouse IgG1 mAb (MOPC 31c, specificity unknown) or (Figure 10B) 100 ng DNP-specific IgE alone. Statistical significance was determined using an unpaired
- 25 Student's t-test: *, $p < 0.05$; **, $p < 0.01$ (actual values 10A, $p = 0.024$ versus MOPC 31c controls; 10B, $p = 0.009$ versus anti-LFA-1β controls).

- Figures 11A-11D are the results of FACS analysis of 3 stable mouse FcγRIII RBL-2H3 transfectants after staining
- 30 with 2.4G2 and FITC-anti-rat IgG.

Figure 12 is a set of graphs illustrating that DNP-HSA induces IgE-mediated degranulation in four different cell lines and that this degranulation is inhibitable by anti-CD81 mAb 5D1.

-7-

DETAILED DESCRIPTION OF THE INVENTION

Mast cells are important effector cells in IgE-dependent immune responses and allergic diseases (Galli, *New. Engl. J. Med.* 328:257-265 (1993)), and mast cells also contribute to host defense against parasites and bacteria (Echtenacher et al., *Nature* 381:75-77 (1996); Galli and Wershil, *Nature* 381:21-22 (1996)). Crosslinking of FcεRI-IgE complexes on mast cells and basophils by multivalent antigen initiates a signaling cascade characterized by tyrosine kinase activation, calcium release and influx and, later, by degranulation and release of inflammatory mediators (Jouvin et al., *J. Biol. Chem.* 269:5918-5925 (1994); Penhallow et al., *J. Biol. Chem.* 270:23362-23365 (1995); Scharenberg et al., *EMBO J.* 14:3385-3394 (1995); Lin et al., *Cell* 85:985-995 (1996); and (Paul et al., *Adv. Immunol.* 53:1-29 (1993)).

Like the B and T cell antigen receptors, FcεRI lacks endogenous signaling capacity and utilizes tyrosine phosphorylation to recruit signaling effector molecules. Receptor aggregation leads to phosphorylation and/or activation of several protein tyrosine kinases (PTKs) Lyn, Syk, Btk, Itk, Fer, and FAK (Jouvin et al., *J. Biol. Chem.* 269:5918-5925 (1994); Penhallow et al., *J. Biol. Chem.* 270:23362-23365 (1995); Scharenberg et al., *EMBO J.* 14:3385-3394 (1995); and Kawakami et al., *Mol. Cell. Biol.* 14:5108-5113 (1994); Kawakami et al., *J. Immunol.* 155:3556-3562 (1995); and Hamawy et al., *J. Biol. Chem.* 268:6851-6854 (1993)), as well as protein kinase C isoenzymes (Ozawa et al., *J. Biol. Chem.* 268:1749-1756 (1993)), MAP kinase (Hirasawa et al., *J. Biol. Chem.* 270:10960-10967 (1995)), and other signaling molecules such as Cbl and Shc (Ota et

-8-

al., *J. Exp. Med.* 184:1713-1723 (1996); and Jabril-Cuenod
et al., *J. Biol. Chem.* 271:16268-16272 (1996)).

The precise role of many of these proteins in
degranulation remains undefined. However, it is clear that
5 FcεRI-mediated calcium mobilization, degranulation, and
leukotriene and cytokine synthesis depend on early tyrosine
kinase activation events, especially the activation of the
PTK Syk. FcεRI signaling is initiated by tyrosine
phosphorylation of immunoreceptor tyrosine-based activation
10 motifs (ITAM; defined by the sequence (D/E)xxYxLxxYx(L/I)
(Flaswinkel et al., *Semin. Immunol* 7:21-27 (1995)).

Phosphorylated ITAMs (pITAMs) facilitate binding of SH2-
domain-containing proteins to FcεRI (Johnson et al., *J.*
Immunol. 155:4596-4603 (1995); Kimura et al., *J. Biol.*
15 *Chem.* 271:27962-27968 (1996)).

In addition to activation events, receptor-activated
PTKs initiate the regulation of antigen receptor signaling
by phosphorylating tyrosine-based motifs on membrane
receptors known as inhibitory receptors (Scharenberg and
20 Kinet, *Cell* 87:951-964 (1996); Cambier, *Proc. Natl. Acad.*
Sci. USA 94:5993-5995 (1997)). These proteins bind SH2-
domain-containing phosphatases, the tyrosine phosphatases
SHP-1 and SHP-2 and the phosphatidylinositol (Scharenberg
et al., *EMBO J.* 14:3385-3394 (1995); Lin et al., *Cell*
25 85:985-995 (1996); Paul et al., *Adv. Immunol.* 53:1-29
(1993)) 5' phosphatase SHIP, upon coengagement with antigen
or growth factor receptors. Although the molecular targets
are still being defined, phosphatase recruitment to
inhibitory receptors has one of two general effects on
30 signaling. Engagement of inhibitory receptors that
preferentially bind SHIP, such as the low affinity receptor
for IgG (FcγRIIb1) (Ono et al., *Nature* 383:263-266 (1996)),

-9-

results in selective inhibition of calcium influx with little or no effect on receptor-mediated calcium release or tyrosine phosphorylation. On the other hand, killer cell inhibitory receptors (KIR) bind SHP-1 upon receptor costimulation, resulting in reduced tyrosine phosphorylation, calcium release from the ER, and calcium influx (Burshtyn et al., *Immunity* 4:77-85 (1996); Binstadt et al., *Immunity* 5:629-638 (1996)). In both mechanisms, calcium mobilization is inhibited along with downstream signaling events.

Descriptions of three representative systems utilized in recent studies are useful for understanding the nature of inhibitory signals, and are outlined in Figures 1A-1C. Briefly, the surface immunoglobulin receptor (sIg) complex and FcγRIIb1 (a low affinity receptor for IgG) are both normally present on B-cell surfaces (Figure 1A, left panel). When sIg receptors are clustered as a result of contact with antigen (Figure 1A, middle panel), they typically produce a cell activation signal which induces B-cell proliferation. However, if the same B-cells are stimulated so that the sIg receptors are co-clustered with FcγRIIb1 receptors (for example by contact of the B-cell with an immune complex of cognate antigen and IgG, Figure 1A, right panel), B-cells fail to proliferate and in some cases may apoptose.

In the natural killer (NK) cell system, a number of cell surface receptors are able to initiate NK cell cytotoxicity, one of which is FcγRIII (Figure 1B, left panel). When an NK cell encounters a target cell, it recognizes and kills the target cell if the target cell lacks class I MHC molecules. One of the ways in which NK cells recognize target cells is by binding of IgG bound to the target cell surface to FcγRIII on NK-cells (Figure 1B, middle panel). If the target cells express appropriate class I MHC

-10-

molecules which can be recognized by appropriate killer cell inhibitory receptors (KIR) on the NK cell, they are protected from cytolysis (Figure 1C, right panel).

In the T-cell system, the T-cell antigen receptor (TCR) and CD4 and/or CD8 co-receptors are normally expressed on the surface of resting T-cells (Figure 1C, left panel). T-cells are activated when their T-cell antigen receptor complexes (TCR's) interact with specific peptide/MHC class II complexes on antigen presenting cells (APCs), resulting in co-clustering of the TCR and CD4 or CD8 (Figure 1C, middle panel). Upon activation, T-lymphocytes upregulate expression of another surface molecule called CTLA-4, which results in interaction of CTLA-4 with its countereceptors CD80 or CD86 (Figure 1C, right panel). Since mice which lack CTLA-4 have hyperactivated T-cells and are prone to lymphoproliferative diseases, it is thought that CTLA-4 mediates an inhibitory signal which provides an important negative feedback control for proliferation and cytokine production induced by T-cell receptor activation signals.

While each of these systems is unique in terms of the manner in which the activating and inhibitory signals are engaged, two common features exist among them: 1) Each involves activating signals mediated by homologous cytoplasmic tail motifs known as immunoreceptor tyrosine based activation motifs (ITAMs). These motifs become tyrosine phosphorylated by src family kinases when the activating receptors are engaged by clustering stimuli, resulting in the recruitment to engaged receptors of both src and syk/zap70 family non-receptor tyrosine kinases. Downstream propagation of the activation signal is then mediated by activation of these tyrosine kinases and the resulting phosphorylation of specific substrates. 2) The inhibitory signals are mediated by separate receptors, such

-11-

as FcγRIIb1, killer cell inhibitory receptors (KIR), and CTLA-4, which are engaged in concert with the activating receptor when an appropriate stimulus is present. When the inhibitory receptors are appropriately engaged, they become phosphorylated on specific cytoplasmic tail tyrosines by src family kinases, which results in the recruitment of signaling molecules which are inhibitory in function.

It appears that SHP-1/SHP-2 and SHIP are recruited for distinct purposes. SHP-1 and SHP-2 attenuate or completely block tyrosine phosphorylation-mediated signals (Figure 3, middle panel), while SHIP allows a full strength tyrosine phosphorylation signal to proceed while blocking any downstream events which require sustained elevations of soluble inositol phosphates and/or intracellular calcium (Figure 3, right panel). One potential explanation can be rationalized by comparing the function of the inhibitory signals mediated by FcγRIIb1 on B-cells and KIR on NK cells. The sIg receptor activating signal serves to notify B-cells that specific antigen is present, and so initiate B-cell maturation and proliferation for the purpose of specific immunoglobulin production. However, coengagement of sIg and FcγRIIb1 blocks proliferation and can induce apoptosis of the B-cell and a consequent decrease in production of specific immunoglobulin, thereby acting as a negative feedback mechanism. Thus, it appears that the persistence of a full strength tyrosine phosphorylation signal in the absence of sustained inositol phosphate and/or intracellular calcium levels is for the purpose of notifying the B-cell that adequate specific antibody has been produced, and may be the signal which induces apoptosis of that B-cell in the appropriate context.

This situation is subtly, but importantly, different than that of an NK cell. NK cells function by undergoing target cell recognition events mediated by activating

-12-

receptors which are capable of initiating cytotoxicity, and the KIR inhibitory signal is required to block inappropriate cytotoxicity of cells which are recognized but which also bear appropriate class I MHC. Since there would be little utility in the NK cell "knowing" about contact with each and every protected target, an inhibitory mechanism where the activating signal is completely abrogated would seem to be most appropriate. This would account for the apparently SHP-1 predominant inhibitory signal mediated by KIR. To summarize, these results suggest that primarily SHP-1/SHP-2 mediated block would be utilized when the cell has no need to know about the presence of a particular stimulus, while a primarily SHIP-mediated block would be utilized when the cell needs to know and to respond in some altered manner.

IgE-dependent activation of mast cells primarily occurs through antigen-mediated crosslinking of IgE-FcεRI complexes which initiates a signaling cascade ultimately leading to release of proinflammatory mediators (Scharenberg and Kinet, *Chem. Immunol.* 61:72-87 (1995)). FcεRI is a member of the multi-subunit, antigen receptor family which includes B and T cell receptors (BCR and TCR) and receptors for the Fc portions of IgA and IgG (Ravetch and Kinet, *Ann. Rev. Immunol.* 9:457-492 (1991)). These receptors share common features of immunoglobulin-like ligand binding subunit(s) and associated signaling polypeptides which lack endogenous enzymatic activity.

In mast cells, both FcεRI and FcγRIII are expressed as αβγ₂ tetramers in which the respective β and Fcγ signaling chains are identical and the ligand-binding α chains are different. In FcεRI, the high affinity IgE binding domain is localized to the FcεRIα subunit (Blank et al., *J. Biol. Chem.* 266:2639-2646 (1991)) and IgE binding to FcεRIα

-13-

itself does not contribute to signaling. The FcεRIβ chain and the FcεRγ homodimer are the signaling components of the FcεRI (αβγ₂) tetrameric receptor. Both FcεRIβ and FcεRγ have one copy per chain of the immunoreceptor

5 tyrosine-based activation motif (ITAM; Flaswinkel et al., *Semin. Immunol.* 7:21-27 (1995), Cambier, *J. Immunol.* 155:3281-3285 (1995)) defined by the sequence Yx2Lx6-7Yx2L/I.

FcεRI signaling is an aggregation-dependent phenomenon
10 in which multivalent antigen crosslinking of IgE-FcεRI complexes initiates a signaling cascade ITAM tyrosine phosphorylation by src family kinases (Shaw et al., *Semin. Immunol.* 7:13-20 (1995)). Signaling through FcεRI is characterized initially by tyrosine phosphorylation of
15 FcεRIβ and FcεRγ ITAMs by the β-associated src family kinase lyn (Jouvin et al., *J. Biol. Chem.* 269:5913-5925 (1994)). The lyn-phosphorylated ITAM (pITAM) interaction results in lyn activation. Direct binding of lyn to fusion proteins containing the FcεRIβ, but not the FcεRγ ITAM, has been
20 demonstrated (Jouvin et al., *J. Biol. Chem.* 269:5918-5925 (1994)). pITAM peptides have been shown to induce lyn phosphorylation both in permeabilized cells and in vitro (Johnsen et al., *J. Immunol.* 155:4596-4603 (1995)).

Following lyn activation, syk is recruited to FcεRγ
25 pITAMs via its SH2 domains where it is phosphorylated and activated (Scharenberg and Kinet, *Chem. Immunol.* 61:72-87 (1995); Jouvin et al., *J. Biol. Chem.* 269:5918-5925 (1994)). FcεRγ pITAM peptides were much more effective than FcεRIβ pITAM peptides at activating syk in vitro in
30 unstimulated RBL-2H3 lysates (Shiue et al., *J. Biol. Chem.* 270:10498-10502 (1995)). Activated lyn and syk

-14-

phosphorylate a number of intracellular substrates including PLC γ 1, BTK, ITK and cbl (Rawlings et al., *Science* 271:822-825 (1996); Kawakami et al., *J. Immunol.* 155:3556-3562 (1995)). Following initial tyrosine kinase activation events, Fc ϵ RI signaling, like that of other antigen receptors, involves calcium release from the endoplasmic reticulum (tyrosine kinase-dependent) and a calcium influx, both of which precede degranulation and the release of preformed mediators by granule fusion with the cytoplasmic membrane. An interesting difference between Fc ϵ RI and other antigen receptors is that calcium mobilization through Fc ϵ RI appears to utilize sphingosine kinase and sphingosine-1-phosphate (S-1-P) (Choi et al., *Nature* 380:634-636 (1996)) as opposed to the classical phospholipase C/InsP3 pathway.

The rat basophilic leukemia cell line, RBL-2H3, has been widely employed as a model cell in the study of Fc ϵ RI-mediated activation. There have been a few reports of monoclonal antibodies (mAbs) directed to membrane components in which co-ligation inhibits Fc ϵ RI-mediated degranulation in mast cells. The best characterized examples are MAFA (mast cell function-associated antigen) (Guthmann et al., *Proc. Natl. Acad. Sci. USA* 92:9397-9401 (1995)) and gp49b1 (Katz et al., *Proc. Natl. Acad. Sci. USA* 93:10809-10814 (1996)). MAFA is an Mr 20 kd C-type lectin expressed in RBL-2H3 cells both as a monomer and disulphide-linked homodimer that inhibits degranulation by acting upstream of Fc ϵ RI-mediated activation of phospholipase C γ 1 activation by tyrosine kinases (Guthmann et al., *Proc. Natl. Acad. Sci. USA* 92:9397-9401 (1995)).

The target of gp49B1 is less well defined; however it appears to act via a tyrosine-based ITIM (immunoreceptor tyrosine-based inhibitory motif) defined by the sequence

-15-

V/Ix2Yx2I/L utilized by the NK inhibitory receptor (KIR), CD22, CTLA-4, and FcγRIIβ1. Tyrosine phosphorylation of the ITIM in KIR induces binding of the SHP-1 tyrosine phosphatase. SHP-1 recruitment is intimately associated with inhibition of calcium influx and mobilization presumably enacted through yet-to-defined dephosphorylation events. Overexpression of phosphatase-inactive SHP-1 ablates the inhibitory activity of endogenous SHP-1. ITIM-mediated recruitment is not restricted to SHP-1, as a second SH2-containing phosphatase (SHP-2) is utilized by CTLA-4, and the FcγRIIb1 ITIM binds either SHP-1 or the SH2-containing inositol phosphatase (SHIP). In the case of gp49b1, it is unclear which effector is being utilized but it has been demonstrated that a splice variant (gp49A) which lacks the cytoplasmic ITIM but is identical in the extracellular domains lacks detectable inhibitory activity. In addition to MAFA, antibodies to the glycolipid Gd1b and the AD1 antigen (rat homologue of CD63) have also been described to inhibit FcεRI-mediated degranulation in RBL-2H3 cells.

Clustering of the high affinity IgE receptor (FcεRI) by antigen initiates a signaling cascade characterized by tyrosine kinase activation, calcium release and influx and, later, by degranulation and release of inflammatory mediators. In order to examine how FcεRI signaling is negatively regulated, a panel of monoclonal antibodies to mast cell membrane antigens was generated and screened for inhibition of IgE-mediated mast cell degranulation. Two degranulation inhibitory antibodies, designated 1A12 and 5D1, immunoprecipitated a Mr 25 kd protein from surface-iodinated rat basophilic leukemia (RBL-2H3) cells. Lys-C peptide sequence obtained from 1A12-immunoaffinity purified immunoprecipitates was found to be highly homologous to mouse and human CD81. Subsequent cloning and

-16-

expression of rat CD81 cDNA from RBL-2H3 confirmed that 1A12 and 5D1 recognize rat CD81 and that CD81 crosslinking inhibits FcεRI-mediated mast cell degranulation.

Signaling through the high affinity receptor for
5 immunoglobulin E (FcεRI) results in the coordinate
activation of tyrosine kinases prior to calcium
mobilization. Receptors capable of interfering with the
signaling of antigen receptors, such as FcεRI, recruit
tyrosine and inositol phosphatases that results in
10 diminished calcium mobilization. It is shown herein that
antibodies recognizing CD81 inhibit FcεRI-mediated mast
cell degranulation but, surprisingly, without affecting
aggregation-dependent tyrosine phosphorylation, calcium
mobilization, or leukotriene synthesis. Furthermore, CD81
15 antibodies also inhibit mast cell degranulation in vivo as
measured by reduced passive cutaneous anaphylaxis
responses. These results reveal an unsuspected calcium-
independent pathway of antigen receptor regulation which is
accessible to engagement by membrane proteins and on which
20 novel therapeutic approaches to allergic diseases can be
based.

CD81 belongs to the transmembrane 4 superfamily
(TM4SF) which includes CD9, CD53, CD63 and CD82 (Wright and
Tomlinson, *Immunol. Today* 15:588-594 (1994)). TM4SF
25 proteins have been found to associate with HLA-DR, CD4,
CD19/21/Leu-13, small GTP-binding proteins and an
unidentified tyrosine phosphatase and (via mAb
crosslinking) to induce calcium mobilization and activate
syk.

30 CD81 is broadly expressed on hematopoietic cells (T
and B lymphocytes, granulocytes, monocytes) and on some
non-lymphoid tumors. The function of CD81 (or other TM4SF
proteins) is incompletely understood, although CD81 appears
to modulate the signaling of other membrane receptors.

CD81 is found in the CD19/CD21 complex on B cells, and mAbs to CD81 or CD19 have been reported to reduce the threshold for B cell receptor signaling (Fearon and Carter, *Annu. Rev. Immunol.* 13:127-149 (1995)) and enhance B cell adhesion via VLA4 (Behr and Schriever, *J. Exp. Med.* 182:1191-1199 (1995)). Consistent with a costimulatory role in B cell receptor signaling, CD81 $-/-$ mice express lower levels of CD19 on B cells which is proposed to contribute to a defect in humoral immunity (Maecker and Levy, *J. Exp. Med.* 185:1505-1510 (1997)). For T lineage cells, both stimulatory and inhibitory activities for anti-CD81 mAbs have been reported (Secrist et al., *Eur. J. Immunol.* 26:1435-1442 (1996); Todd et al., *J. Exp. Med.* 184:2055-2060 (1996); Oren et al., *Mol. Cell. Biol.* 10:4007-4015 (1990); and Boismenu et al., *Science* 271:198-200 (1996)). CD81 ligation enhances IL-4 production from antigen-specific CD4 $^{+}$ T cells (Secrist et al., *Eur. J. Immunol.* 26:1435-1442 (1996)) and integrin activation and IL 2-dependent proliferation in human thymocytes (Todd et al., *J. Exp. Med.* 184:2055-2060 (1996)). Alternatively, CD81 was originally called TAPA-1 (target of antiproliferative antibody) based on inhibition of proliferation in human T cell lines by CD81 antibodies (Oren et al., *Mol. Cell. Biol.* 10:4007-4015 (1990)). Some of these pleiotropic effects may stem from the potential signaling molecules with which CD81 has been reported to associate including CD4, CD8, MHC class II, other TM4SF proteins, integrin VLA4, and phosphatidylinositol 4-kinase (Wright and Tomlinson, *Immunol. Today* 15:588-594 (1994); Imai et al., *J. Immunol.* 155:1229-1239 (1995); Angelisova et al., *Immunogenetics* 39:249-256 (1994); Mannion et al.,

-18-

J. Immunol. 157:2039-2047 (1996); and Barditchhevski et al.,
J. Biol. Chem. 272:2595-2598 (1997)).

Mast cell FcεRI can be saturated with monoclonal IgE
antibodies. In the absence of crosslinking by appropriate
5 antigen, IgE binding to FcεRI does not activate mast cells.
Monoclonal antibodies are purified from culture
supernatants or mouse ascitic fluid (produced by injection
of antibody-producing cells into immunocompromised mice by
standard techniques, such as those described in Kohler and
10 Milstein, *Nature* 256:495-497 (1975); Kozbar et al.,
Immunology Today 4:72 (1983); and Cole et al., *Monoclonal
Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-
96 (1985)). Crosslinking by the antigen (protein binding
to the IgE) normally induces cell degranulation which can
15 be quantitated by enzyme assay or radioactivity release
assay. Antibody treatment of CD81 mast cells inhibits IgE-
mediated degranulation; 20 ng of 5D1 monoclonal antibody
per 10⁶ RBL-2H3 cells inhibits degranulation through IgE-
mediated channels by greater than 75%.

20 Mast cells are a major cell in allergic reactions.
Thus, the present invention can be used to develop agents,
e.g., antibodies, which inhibit the allergic process, as
well as to develop compounds for the treatment of
allergies, anaphylactic reactions and related diseases.
25 Agents can also be developed which mimic the process of
CD81-mediated inhibition of mast cell degranulation. Anti-
CD81 antibodies are more inhibitory than antibodies to
other different proteins for IgE-mediated degranulation,
particularly because anti-CD81 antibodies act directly and
30 do not require secondary reagents. The work described
herein can also be used to develop model systems for the
study of activation of mast cells through the FcεRI

-19-

receptor and to improve the therapeutic capability to modulate the function of these cells

Agents described herein can be anything which binds to or interacts with CD81 and induces (i.e., activates) or enhances CD81-mediated signal transduction. For example, the agent can be a small molecule, a peptide, or a polyclonal or monoclonal antibody, such as an anti-CD81 antibody. In particular embodiments, the antibody is 5D1 or 1A12.

10 In order to identify membrane proteins capable of regulating FcεRI signaling, mAbs to the rat basophilic leukemia (RBL 2H3) cell line were produced and antibodies which inhibited FcεRI-mediated degranulation were identified. The results are shown in Figures 7A-7D. Cells
15 were preincubated with mAb 5D1 or buffer for 30 minutes (Figures 7A, 7B, 7D) or for the indicated times (Figure 7C) at room temperature prior to triggering for 30 minutes (Figures 7A-7C) or as indicated (Figure 7D). The data shown are representative of more than 10 experiments with
20 the 5D1 mAb. As shown in Figure 7A, pretreatment of anti-DNP IgE-saturated RBL-2H3 cells with purified mAb 5D1 inhibited FcεRI-mediated degranulation by 75% as measured by release of granule-stored ³H-serotonin. Blockage of serotonin release was significant (*, p<0.05) even at
25 subsaturating concentrations of 5D1 (2.5 nM mAb/10⁵ cells, Figure 7A). 5D1-mediated inhibition was specific for FcεRI signaling, as degranulation induced by phorbol myristate acetate (PMA) and calcium ionophore ionomycin were unaffected (Figure 7B). Furthermore, maximal inhibition of
30 FcεRI-mediated degranulation by mAb 5D1 required only brief periods of preincubation (Figure 7C), and inhibition was sustained for at least one hour of antigen stimulation (Figure 7D).

The protein recognized by the degranulation-inhibitory 5D1 mAb was then identified. 5D1 and a second degranulation-inhibitory mAb (1A12) recognized proteins of Mr 25 kDa. 5D1 and 1A12 blocked each others' binding to RBL-2H3 cells, although neither mAb inhibited IgE binding and, conversely saturation of FcεRI with IgE had no effect on 1A12 binding, suggesting that 1A12 and 5D1 recognized the same protein (see Figure 8) and that FcεRI and the 1A12/5D1 antigen were not co-localized on the cell membrane. Since mAb 1A12 was more effective at immunoprecipitation and on Western blots, it was used for protein purification. Batch preparations of RBL-2H3 extracts were immunoprecipitated with mAb 1A12, resolved on preparative SDS-PAGE and transferred to nitrocellulose for protein sequencing. Peptide sequence obtained from Lys-C digests of 1A12 immunoprecipitates is shown aligned with homologous sequences from mouse and human CD81 in Figure 5. Based on these data, rat CD81 was cloned from a RBL-2H3 cDNA library using mouse CD81 cDNA as a probe and expressed in the mouse mast cell line C11.MC/C57.1 (Young et al., *Proc. Natl. Acad. Sci. USA* 84:9175-9179 (1987)). FACS profiles of C11.MC/C57.1 transfectants are shown in Figure 8; both degranulation-inhibitory mAbs 1A12 and 5D1 recognized rat CD81.

To target the site of CD81 inhibition of degranulation, the effect of CD81 antibodies on the earliest events of FcεRI signal transduction, i.e. tyrosine phosphorylation of proteins by activated, nonreceptor tyrosine kinases including Lyn and Syk, and calcium mobilization (Jouvin et al., *J. Biol. Chem.* 269:5918-5925 (1994); Penhallow et al., *J. Biol. Chem.* 270:23362-23365 (1995); Scharenberg et al., *EMBO J.* 14:3385-3394 (1995); Lin et al., *Cell* 85:985-995 (1996)) was examined. In these

experiments, IgE-saturated RBL-2H3 cells were pretreated with purified anti-CD81 prior to triggering with DNP-HSA for the indicated periods of time, followed by extraction and immunoprecipitation of total tyrosine-phosphorylated proteins. No major changes in the pattern of FcεRI induced tyrosine phosphorylation were detected with anti-CD81 treatment prior to antigen triggering. Incubation of RBL-2H3 cells with 5D1 alone (no antigen triggering) did not induce detectable tyrosine phosphorylation.

The effect of anti-CD81 on FcεRI-induced calcium mobilization was monitored on individual, adherent RBL-2H3 cells by confocal microscopy in cells loaded with calcium dye fluo-3. As shown in Figure 9A, no inhibition of FcεRI-induced calcium mobilization in anti-CD81 treated versus controls was observed by confocal microscopy, despite inhibition of degranulation under these conditions (Figure 9B). Anti-CD81 pretreatment had no effect on calcium release from intracellular stores in cells triggered in Ca²⁺-free buffer containing 0.5 mM EGTA or on pre-triggering baseline values. Similar results were also obtained with RBL-2H3 triggered through FcεRI in suspension using a spectrophotometer. In separate experiments, anti-CD81 mAb 5D1 did not inhibit leukotriene C₄ (LTC₄) production induced by DNP-HSA/IgE stimulation (Figure 9C). LTC₄ production is dependent on activation of phospholipase A₂ (tyrosine kinase and calcium-dependent) and is regulated by PMA-sensitive, protein kinase C isozymes (Currie et al., *Biochem. J.* 304:923-928 (1994)); Ali et al., *J. Immunol.* 153:776-788 (1994)). These data suggest that CD81 acts independently of early tyrosine phosphorylation and calcium mobilization events which are critical for mast cell degranulation.

These results were unexpected in light of the reported modes of action of other inhibitory receptors. These

-22-

proteins fall into two major classes: type I, transmembrane proteins that are members of the Ig superfamily (FcγRIIb1, KIR, CTLA-4, CD22, gp49b1, paired Ig-like receptors (PIR), signal-regulatory proteins (SIRPs)) and type II,

- 5 transmembrane, C-type lectins (e.g. Ly-49, NKG2A, mast cell function associated protein (MAFA)) (Ono et al., *Nature* 383:263-266 1996); Burshstyn et al., *Immunity* 4:77-85 (1996)).

- CD81 differs from these inhibitory receptors in three
10 important ways. First, unlike other inhibitory receptors, CD81 inhibits FcεRI-mediated degranulation while leaving both tyrosine phosphorylation and calcium mobilization apparently unaffected. While these results cannot exclude a very selective inhibition of kinase activity by CD81
15 antibodies, it is clear that no detectable effect is found on tyrosine kinase-sensitive calcium mobilization of LTC₄ production. Second, CD81 belongs to a different structural class of proteins than the other inhibitory receptors. CD81 is a TM4SF protein with four transmembrane spanning
20 segments, two extracellular loops, two short cytoplasmic tails, and a short intracellular loop between transmembrane segments 2 and 3 (Wright and Tomlinson, *Immunol. Today* 15:588-594 (1994)). Third, the cytoplasmic tails of CD81 lack ITIM motifs. While there is an ITIM-like sequence
25 (GCYGA1) in the short intracellular loop between transmembrane segments 2 and 3, there is no evidence that this site is phosphorylated by tyrosine kinases or capable of binding to SH2 domains.

- In order to assess the activity of anti-CD81 in FcεRI
30 signaling in normal mast cells, the passive cutaneous anaphylaxis (PCA) model, a classic system for studying mast cell activation *in vivo* (Wershil et al., *J. Immunol.* 154:1391-1398 (1995); Dombrowicz et al., *J. Clin. Invest.*

-23-

99:915-925 (1997)), was chosen. In these experiments, rats were injected intradermally with IgE mixed with anti CD81 mAb 5D1 (IgG1) or with class-matched mouse (IgG1) as control (Figure 10A). Additional rats received anti-DNP IgE alone into the skin at time 0, followed by a second injection (buffer, 5D1, or anti-rat LFA-1 β (IgG1)) (Figure 10B) into IgE-injected sites 21 hours after IgE injections. Twenty four hours after IgE priming, rats received 1 mg of antigen intravenously (DNP-HSA containing 1% Evan's blue dye). Mast cell activation through Fc ϵ RI in PCA results in the release of several vasoactive substances which act to increase vascular permeability, a property which is quantified by local accumulation of the Evan's blue dye from the vasculature into the sites of IgE injections. These results are expressed as μ g Evan's blue converted from A₄₁₆ measurements of formamide-extracted tissue biopsies (Dombrowicz et al., *J. Clin. Invest.* 99:915-925 (1997)). As shown in Figure 10A, coinjection of anti-CD81 mAb 5D1 during IgE priming significantly inhibited IgE-dependent PCA reactions ($p=0.024$) compared to class-matched controls.

To limit the possibility of non-specific suppression of PCA reactions due to tissue deposition of IgG, mAbs, these experiments were repeated by injecting anti-CD81 mAb 5D1 or anti-LFA-1 β (CD18) into the IgE-injected sites 3 hours before antigen administration. LFA-1 β is expressed on mast cell lines including RBL-2H3 but anti-LFA-1 β has no effect on Fc ϵ RI-mediated degranulation in RBL-2H3 cells (Weber et al., *Scand. J. Immunol.* 45:471-481 (1997)). Similar to coinjection of IgE and IgG, mAbs, separate injections of anti-CD81 yielded significant inhibition of PCA reactions compared to anti-LFA-1 β controls (Figure 10B).

Thus, it is demonstrated herein that CD81 is a novel inhibitory receptor for FcεRI. The observation that CD81 acts on calcium-independent events required for mast cell degranulation distinguishes CD81 from previously described
5 inhibitory receptors, such as FcγRIIb1 and KIR, which act upstream of calcium influx. Anti-CD81 mAbs also inhibited IgE-dependent PCA reactions, which suggests the CD81 pathway is present in normal mast cells and capable of being engaged to inhibit mast cell responses *in vivo*.

10 Therefore, the CD81 inhibitory pathway can be utilized in therapeutic strategies aimed at intervention of allergic responses.

RBL-2H3 cells express FcεRI, CD81 and endogenous rat FcγRIII receptors. However, no high-affinity reagent
15 (antibody) is available to trigger the FcγRIII receptors on RBL-2H3; the 2.4G2 antibody (anti-mouse FcγRII/FcγRIII) was used for this purpose. To demonstrate that CD81 stimulation inhibits degranulation induced through FcγRIII signaling as it does for FcεRI, murine FcγRIIIα chain cDNA
20 was expressed in RBL-2H3 cells.

FcγRIII binding of IgG is detectable only when IgG is present in the form of IgG-containing immune complexes which crosslink FcγRIII receptors and initiate
intracellular signals. One of the methods of triggering
25 FcγRIII is through stimulation with crosslinked anti-FcγRIII antibodies. Figure 12 shows the results when RBL-2H3 and FcγRIII-transfectants of RBL-2H3 were loaded with ³H-serotonin in the presence (DNP-HSA stimulation) or absence (immune complex stimulation) of DNP-specific IgE.
30 After overnight incubation, cells were washed and incubated with culture media or media containing 200 ng of anti-rat CD81 mAb 5D1 prior to triggering with optimized concentrations of DNP-HSA or with preformed immune complexes of 2.4G2/anti-rat IgG F(ab'). Degranulation was

-25-

allowed to proceed for 30 minutes at 37°C and released H
serotonin was quantitated by scintillation counting. As
shown in Figure 12, DNP-HSA induces IgE-mediated
degranulation in all four cell lines which is inhibitable
5 by anti-CD81 mAb 5D1. 2.4G2/anti-rat IgG F(ab')₂ preformed
complexes, but not anti-rat IgG F(ab)₂ alone, induce
degranulation only in cells expressing α Fc γ RIII receptors
(RBL-2H3 transfectants A10, D10 and H11), a process which
is also inhibitable by preincubation with 5D1. This data
10 provides the identification of CD81 as a common inhibitor
of both Fc ϵ RI and Fc γ RIII.

Accordingly, the present invention relates to a method
of inhibiting or enhancing cell surface receptor signaling,
e.g., Fc ϵ RI-mediated or Fc γ RIII-mediated signaling. The
15 method of inhibiting cell surface receptor signaling
comprises contacting a cell with an effective amount of an
agent which enhances or induces CD81-mediated signal
transduction. Alternatively, the method can be a method of
inhibiting cell surface receptor signaling in a mammal,
20 comprising administering to the mammal an effective amount
of an agent which enhances or induces CD81 mediated signal
transduction. Appropriate cells are any cell type which
expresses or has been designed to express (e.g., by
transfection or genetic engineering) both CD81 and a
25 suitable cell surface receptor.

For example, inhibition of the cell surface receptor
signals which induce mast cell degranulation is useful in
methods of treating allergic conditions or inflammatory
disorders. Enhancement of the cell surface receptors which
30 induce mast cell degranulation is useful in inducing an
inflammatory response, for example, in response to
bacterial or parasite infection.

The method of enhancing cell surface receptor
signaling comprises contacting a cell with an effective

-44-

amount of an agent which inhibits or prevents CD81-mediated signal transduction. Alternatively, the method can be a method of enhancing cell surface receptor signaling in a mammal, comprising administering to the mammal an effective amount of an agent which inhibits or prevents CD81-mediated signal transduction. It may be clinically beneficial to enhance cell surface receptor signaling in a mammal, or the functional results thereof, such as degranulation, in conditions where an inflammatory response and/or release of leukotrienes and cytokines is beneficial, such as in host defense against parasites and bacteria.

The invention also pertains to a method of treating an allergy (e.g., asthma, hay fever or atopic eczema) or inflammatory condition in a mammal comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction. For example, the method can be used to treat allergic or inflammatory responses associated with disorders such as autoimmune (Type 1) diabetes mellitus, rheumatoid arthritis, ankylosing spondylitis, sarcoidosis, Sjögren's syndrome, multiple sclerosis, inflammatory bowel disease (i.e., Crohn's disease and ulcerative colitis), dermatomyositis, scleroderma, polymyositis, systemic lupus erythematosus, biliary cirrhosis, autoimmune thyroiditis, and autoimmune hepatitis, as well as many dermatological disorders, including psoriasis, contact sensitivity and atopic dermatitis.

As used herein, "inhibit" is intended to encompass any qualitative or quantitative reduction in a measured effect or characteristic, including complete prevention, relative to a control. As also used herein, "enhance" is intended to encompass any qualitative or quantitative increase in a measured effect or characteristic relative to a control. An "effective amount" of a given agent is intended to mean

-27-

an amount sufficient to achieve the desired effect, e.g., the desired therapeutic effect, under the conditions of administration, such as an amount sufficient for inhibition or enhancement of CD81-mediated signal transduction.

5 The present invention also relates to preparations for use in the inhibition or enhancement of cell surface receptor signaling, and the treatment of allergic diseases and inflammatory disorders, the preparation including an inhibitor or promoter of CD81-mediated signal transduction,
10 together with a physiologically acceptable carrier and optionally other physiologically acceptable adjuvants.

According to the method, a therapeutically effective amount of one or more agents (e.g., a preparation comprising an inhibitor or promoter of CD81-mediated signal
15 transduction can be administered to an individual by an appropriate route, either alone or in combination with another drug.

A variety of routes of administration are possible including, but not limited to, oral, dietary, topical,
20 parenteral (e.g., intravenous, intraarterial, intramuscular, subcutaneous injection), and inhalation (e.g., intrabronchial, intranasal or oral inhalation, intranasal drops) routes of administration, depending on the agent and disease or condition to be treated. For
25 respiratory allergic diseases such as asthma, inhalation is a preferred mode of administration.

Formulation of an agent to be administered will vary according to the route of administration selected (e.g., solution, emulsion, capsule). An appropriate composition
30 comprising the agent to be administered can be prepared in a physiologically acceptable vehicle or carrier. For solutions or emulsions, suitable carriers include, for example, aqueous or alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.

-25-

Parenteral vehicles can include sodium chloride solution, Binger's dextrose, dextrose and sodium chloride, lactated Binger's or fixed oils, for instance. Intravenous vehicles can include various additives, preservatives, or fluid, nutrient or electrolyte replenishers and the like (See, generally, *Remington's Pharmaceutical Sciences*, 17th Edition, Mack Publishing Co., PA, 1985). For inhalation, the agent can be solubilized and loaded into a suitable dispenser for administration (e.g., an atomizer, nebulizer or pressurized aerosol dispenser).

Furthermore, where the agent is a protein or peptide, the agent can be administered via *in vivo* expression of the recombinant protein. *In vivo* expression can be accomplished via somatic cell expression according to suitable methods (see, e.g. U.S. Patent No. 5,399,346). In this embodiment, nucleic acid encoding the protein can be incorporated into a retroviral, adenoviral or other suitable vector (preferably, a replication deficient infectious vector) for delivery, or can be introduced into a transfected or transformed host cell capable of expressing the protein for delivery. In the latter embodiment, the cells can be implanted (alone or in a barrier device), injected or otherwise introduced in an amount effective to express the protein in a therapeutically effective amount.

The invention also pertains to assays for identifying agents which enhance or inhibit calcium independent CD81-mediated signal transduction. The assay comprises combining a cell bearing CD81 with an agent to be tested, under conditions suitable for signal transduction by CD81. The level or extent of CD81-mediated signal transduction can be measured using standard methods and compared with the level or extent of CD81-mediated signal transduction in the absence of the agent (control). An increase in the

-29-

level or extent of CD81-mediated signal transduction relative to the control indicates that the agent is a promoter of CD81-mediated signal transduction; a decrease in the level or extent of CD81-mediated signal transduction relative to the control indicates that the agent is an inhibitor of CD81-mediated signal transduction.

Inhibitors or promoters of CD81-mediated signal transduction, e.g., those identified by methods described herein, can be assessed to determine their effect on cell surface receptor signaling. Inhibitors or promoters of CD81-mediated regulation of cell surface receptor signaling can be, for example, small molecules, antibodies and/or peptides. A cell bearing CD81 and an appropriate cell surface receptor (e.g., FcεRI or FcγRIII) are combined with an inhibitor or promoter of CD81-mediated signal transduction under conditions suitable for signal transduction by both CD81 and the cell surface receptor. The level or extent of cell surface receptor signaling can be measured using standard methods and compared with the level or extent of cell surface receptor signaling in the absence of the inhibitor or promoter (control). An increase in the level or extent of cell surface receptor signaling relative to the control indicates that the agent is a promoter of cell surface receptor signaling; a decrease in the level or extent of cell surface receptor signaling relative to the control indicates that the agent is an inhibitor of cell surface receptor signaling.

Cell surface receptor signaling can be measured directly, such as by measuring the level or amount of an associated signalling molecule, or indirectly, such as by a functional assay measuring level or amount of degranulation or passive cutaneous anaphylaxis.

The following Examples are offered for the purpose of illustrating the present invention and are not to be

construed to limit the scope of this invention. The teachings of all references cited herein are hereby incorporated herein by reference.

EXAMPLES

5 Cell Culture, Reagents and Antibodies

The rat basophilic leukemia cell line (RBL-2H3) was cultured in EMEM supplemented with 16% heat-inactivated FCS, 2 mM L-glutamine and penicillin (100 U/ml)/streptomycin (50 mg/ml) (Biofluids, Rockville, MD).

- 10 NS-1 and SP2/0 myeloma cells were cultured in RPMI 1640 supplemented with 20% FCS, glutamine and antibiotics. C1.1C3/C57.1 cells were cultured as described in Young *et al.* (*Proc. Natl. Acad. Sci. USA* 84:9175-9179 (1987)). DNP human serum albumin (DNP-HSA) (30-40 moles DNP/mole albumin) was purchased from Sigma Chemical Co. (St. Louis, MO). DNP-specific IgE supernatants were used to saturate FcγR1 as described in Young *et al.* (*Proc. Natl. Acad. Sci. USA* 84:9175-9179 (1987)). For PCA experiments, MOPC31c (IgG₁) and anti-DNP-mouse IgE (clone SPF-7) were purchased from Sigma Chemical Co. (St. Louis, MO) and anti-rat β2 integrin (anti-LFA-1β, CD18; clone WT.3) was purchased from Pharmingen (San Diego, CA). MOPC 31c and anti-DNP IgE were dialyzed to remove sodium azide before *in vivo* injections. Anti-rat CD31 (5D1, IgG₁) was purified from ascites on
- 25 Protein G Sepharose (Pharmacia, Uppsala, Sweden).

Immunizations, Fusions, and FACS

- Female BALB/c mice (4-8 weeks old) were immunized intraperitoneally with 25×10^6 RBL-2H3 emulsified in complete Freund's adjuvant or 50×10^6 in PBS. Mice were
- 30 boosted after 2 weeks with 40×10^6 RBL-2H3 cells emulsified in incomplete Freund's adjuvant

-31-

intraperitoneally or in PBS. For the final immunizations, animals were injected with $20-40 \times 10^6$ RBL-2H3 cells intraperitoneally at day -4 (fusion = day 0) and intravenous at day -3. Spleen cell preparations were fused with either NS-1 or SP2/0 myeloma cells in polyethylene glycol and plated onto normal BALB/c spleen feeder cells. To enhance the development of the hybridomas, *S. typhimurium* mitogen (Ribi ImmunoChem Research, Inc., Natick, MA) was included in the culture medium from days 0-10. Hybridoma supernatants were tested after day 14 by flow cytometry for binding to RBL-2H3 using FITC-conjugated goat anti-mouse F(ab')₂-specific antibody (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and analyzed by flow cytometry on a FACSCAN™ flow cytometer (Becton-Dickinson, San Jose, CA).

From 3 separate fusions, a total of 2160 wells were plated and 622 supernatants from wells with hybridoma growth were screened by FACS for reactivity with RBL-2H3 cells. In all, 283/622 (45%) elicited detectable reactivity by FACS with membrane antigens of RBL-2H3. The screening of RBL-2H3-reactive mAbs by serotonin release assay lead to the identification of 1A12 (IgG₁) and 5D1 (IgG₁), which were characterized further. Rat CD81 transfectants of were stained with purified 1A12 and 5D1 (1μg/10⁶ cells), counterstained with goat anti-mouse F(ab')₂-specific antibody and analyzed by flow cytometry on a FACScan® flow cytometer.

Serotonin Release Assay and Leukotriene C4 Assays

RBL-2H3 cells were loaded with [³H]-5-hydroxytryptamine (30 [³H]-serotonin; 0.1-0.3 mCi/10⁶ cells) and saturated with DNP-specific IgE in 96-well microtiter tissue culture plates (10⁵ cells/well, 37°C, 5% CO₂) as described in Baron et al. (J. Immunol. 149:1365-1373 (1992)).

- 32 -

Monolayers were washed three times with buffer (glucose-saline, PIPES buffer (pH 7.2) containing (in mM) 25 PIPES, 110 NaCl, 5 KCl, 5.6 glucose, 0.4 MgCl₂, 1 CaCl₂ and 0.1% BSA), and 25 ml of a dilution of purified antibody was added to the labeled monolayers, and plates were incubated for 30 minutes (or as indicated) at room temperature. Triggering of FcεRI was performed by the addition of DNP-HSA (final concentration 10-250 ng/ml) and plates were incubated at 37°C (except as indicated in Figure 7D) with control samples present on each plate. Degranulation was stopped by placing the plates on ice and by the addition of 150 µl of cold culture medium per well. 100 µl aliquots were taken from replicate wells for scintillation counting. Total cellular incorporation was determined from 1% SDS/1% NP-40 lysates.

Leukotriene C₄ was measured from 10⁶ anti-DNP IgE saturated RBL-2H3 treated with 1 µg 5DI or buffer prior to triggering with 30 ng/ml DNP-HSA. Supernatants were stored at -80°C until measurement of LTC₄ by specific enzyme immunoassay (Cayman Chemical, Ann Arbor, MI).

Immunoaffinity Chromatography, Electrophoresis, and Western Blotting

RBL-2H3 cells were cultured in routine culture medium in spinner flasks to a cell density of approximately 10⁶/ml, harvested by centrifugation and washed twice with cold PBS. Washed cells were extracted in 0.5 M K₂HPO₄ (pH 7.5) with proteinase inhibitors (10 µg/ml pepstatin, 5 µg/ml leupeptin, and 10 µg/ml aprotinin) at 50 x 10⁶/ml for 60 minutes at 4°C with frequent mixing. N-ethylglucoside (10 mM) was added during the extraction to ensure protein solubility. Post-nuclear lysates were prepared by centrifugation at 15,000 x g for 20 minutes at 4°C. Lysates were then passed through 0.2 µm filters to remove

-33-

residual debris and passed several times over protein G-Sepharose coupled to 1A12 (2 mg/ml bed volume), washed with PBS (10 mM n-octylglucoside) and eluted with 0.2 M glycine. Tris-neutralized, concentrated extracts were reduced with 5 2-mercaptoethanol, resolved on 12.5% preparative SDS-PAGE and transferred to ImmobilonTM (Millipore, Bedford, MA). The membrane was stained with amido black and the Mr 25 kDa band was excised, eluted, alkylated and digested overnight with Lys-C. Peptides were separated by reverse phase-HPLC 10 and the peptide peak eluting at 36 minutes was sequenced. Subsequent cloning and expression of rat CD81 cDNA from RBL-2H3 confirmed that 1A12 and 5D1 recognize rat CD81 and that CD81 crosslinking inhibits FcεRI-mediated mast cell degranulation.

15 For anti-phosphotyrosine Western blots, 0.5% Triton X-100 (BBS, proteinase inhibitors) extracts were immunoprecipitated overnight with 2 µg of anti-phosphotyrosine mAb 4G10 bound to protein A-Sepharose beads (4°C with rotation). Beads were washed with lysis buffer, 20 eluted, resolved on 12.5% SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted with 1 µg/ml 4G10 mAb, followed by incubation with HRP-conjugated anti-mouse IgG secondary antibodies and development with chemiluminescence substrates (Renaissance, Dupont/NEN, 25 Boston, MA).

Construction and Screening of RBL-2H3 cDNA library in UNI-ZAPTM

Poly A+ mRNA was isolated from RBL-2H3, reverse-transcribed into cDNA, size-fractionated on Sephacryl S-500 30 spin columns and ligated into UNI-ZAP-XR lambda vector according to the manufacturer's instructions (Stratagene, La Jolla, CA). After rescue of the cDNA inserts and appropriate restriction enzyme digests, it was determined

34-

that 96% of the plasmids contained inserts, with an average size of 1.7 kb. 5×10^5 plaques were screened with ³²P-labeled mouse CD81 cDNA probe. After hybridization, nitrocellulose filters were washed once with 2x SSC containing 0.1% SDS (room temperature) and 3 times with 0.5x SSC containing 0.1% SDS at 50°C. Filters were autoradiographed and plaques picked and eluted. Candidate plaques were subjected to three additional rounds of plaque purification before rescue of the cDNA inserts into pBluescript. Sequencing was performed on eleven isolates and all were found to align with accession number U19894 isolated from rat brain (Geisert, Jr., et al., *Neurosci. Lett.* 133:262-266 (1991); Irwin and Geisert, Jr., *Neurosci. Lett.* 154:57-60 (1993); Geisert, Jr., et al., *J. Neurosci.* 16:5478-5487 (1996)).

Transfections: Rat CD81 cDNA from two isolates was subcloned into the pBJuno expression vector (Lin et al., *Cell* 85:985-995 (1996)) and 20 µg of ethanol-precipitated DNA was used for electroporation of C1.MC/C57.1 cells (1050 µF, 270v). Selection of stable transfectants was initiated 48 hours later by replating at 500-10,000 cells per well with 2 mg/ml G418 (Life Technologies, Grand Island, NY).

Confocal Microscopy: After overnight adherence and saturation of FcεRI with DNP-specific IgE, RBL-2H3 cells were washed with buffer and incubated with 3 µM fluo3/AM (Molecular Probes, Eugene, OR) and 0.2 mg/ml Pluronic (Molecular Probes) at 37°C for 30 minutes (5% CO₂) in a buffer containing 140 mM NaCl, 5 mM KCl, 1 mM MgCl₂, 1 mM CaCl₂, 10 mM glucose, and 1 mM Na-HEPES (pH 7.4). Dye-loaded cells were then washed once with the same buffer before preincubation (30 minutes, room temperature) with buffer (+5D1, 1 µg/chamber/10⁵ cells) and triggering with 100 ng/ml DNP-HSA. Ca²⁺ measurements in single cells were

monitored using a laser-scanning confocal microscope (LSM4, Zeiss, New York, NY) equipped with an argon/krypton laser to excite the dye at 488 nm. Fluorescence emission above 510 nm was measured after placing a long pass filter in front of the photomultiplier tube. The confocal system was employed in slow scan mode and fluorescence images were collected every 5 seconds. Fluorescence measurements were normalized by dividing the average fluorescence intensity (F) occurring during the course of the experiment to the average fluorescence intensity determined at the beginning of the experiment (F_0). All measurements were performed at 22-24°C.

Passive Cutaneous Anaphylaxis in Rats

Male Wistar rats (275-300 g) were used in these experiments. Rats were first anesthetized with ether, then back skin hair was shaved and rats were injected intradermally with 50 μ l containing 100 ng anti-DNP IgE or 25 ng anti-DNP-IgE mixed with 50 μ g of MOPE 31c (mouse IgG₁, specificity unknown) or 5D1 (mouse IgG₁, anti-rat CD81). Control sites received buffer alone (PBS containing 10 μ g/ml mouse serum albumin; Sigma Chemical Co., St. Louis, MO). Sites were marked on the skin for orientation and rats that received 100 ng anti-DNP injections received a second injection 21 hours later with 50 μ g of 5D1 or anti-rat LFA-1 β (CD18; mouse IgG₁) into previously injected sites. Sites receiving IgE and IgG₁ were injected in triplicate on the same rat. Twenty-four hours after IgE injections, animals received 1 ml of 1 mg/ml DNP-HSA containing 1% Evan's Blue dye injected intravenously under ether anesthesia. Thirty minutes after intravenous injection, rats were sacrificed, and punch biopsies (2.5 cm²) were obtained, minced and extracted 3 times with hot formamide (80°C, 3 hours) (Dombrowicz et al., *J. Clin.*

-36-

Invest. 99:915-925 (1997)). Pooled samples from tissue sites were centrifuged and absorbance at 610 nm (A_{610}) was measured. A_{610} values were converted to μ g Evan's blue based on a standard curve of dilutions of Evan's Blue in 5 formamide.

Inhibition of Signaling Elicited Through the Low Affinity IgG Receptor Fc γ RIII

RBL-2H3 cells express Fc ϵ RI, CD81 and endogenous rat Fc γ RIII receptors. However, no high-affinity reagent (antibody) is available to trigger these receptors on RBL-2H3; the 2.4G2 antibody (anti-mouse Fc γ RII/Fc γ RIII) was used for this purpose. To demonstrate that CD81 stimulation inhibits degranulation induced through Fc γ RIII signaling as it does for Fc ϵ RI, murine Fc γ RIII α chain cDNA was expressed in RBL-2H3 cells. Fc ϵ γ cDNA was cotransfected to assist in the surface expression of Fc γ RIII complexes. In Figures 11A-11D, the histograms of 3 stable mouse Fc γ RIII RBL-2H3 transfectants are shown after staining with 2.4G2 and FITC-anti-rat IgG. Untransfected RBL-2H3 cells exhibit no detectable binding of 2.4G2 (Figure 11A).

Fc γ RIII binding of IgG is detectable only when IgG is present in the form of IgG-containing immune complexes which crosslink Fc γ RIII receptors and initiate intracellular signals. One of the methods of triggering Fc γ RIII is through stimulation with crosslinked anti-Fc γ RIII antibodies. In Figure 12, RBL-2H3 and Fc γ RIII transfectants of RBL-2H3 were loaded with 3 H-serotonin in the presence (DNP-HSA stimulation) or absence (immune complex stimulation) of DNP-specific IgE. After overnight incubation, cells were washed and incubated with culture media or media containing 200 ng of anti-rat CD81 mAb 5D1 prior to triggering with optimized concentrations of DNP-

- 37 -

HSA or with preformed immune complexes of 2.4G2/anti-rat IgG F(ab')₂. Degranulation was allowed to proceed for 30 minutes at 37°C and released ³H-serotonin was quantitated by scintillation counting. As shown in Figure 12, DNP-HSA induces IgE-mediated degranulation in all four cell lines which is inhibitable by anti-CD81 mAb 5D1. 2.4G2/anti rat IgG F(ab')₂ preformed complexes, but not anti-rat IgG F(ab')₂ alone, induce degranulation only in cells expressing mFcγRIII receptors (RBL-2H3 transfectants A10, D10 and H11), a process which is also inhibitable by preincubation with 5D1. This data provides the identification of CD81 as a common inhibitor of both FcεRI and FcγRIII.

RESULTS

5D1 mAb inhibits FcεRI-mediated degranulation by antigen. From 3 separate fusions, a total of 2160 wells were plated and 622 supernatants from wells with hybridoma growth were screened by FACS for reactivity with the immunizing RBL-2H3 cells (see Table 1). In all, 283/622 elicited detectable reactivity by FACS with membrane antigens of RBL-2H3. Supernatants from the positive hybridomas were then tested for inhibition of FcεRI-mediated degranulation. RBL-2H3 cells exhibit a reproducible degranulation profile to FcεRI-IgE stimulation by the corresponding antigen DNP-HSA. Detectable serotonin release is observed with 1 ng/ml concentrations of DNP-HSA; maximal serotonin release occurs with approximately 50 ng/ml, and at concentrations greater than 1 mg/ml DNP-HSA degranulation is inhibited, presumably because of the diminished ability of large FcεRI-IgE aggregates to signal. In Figure 4, purified 5D1 mAb inhibits IgE-mediated degranulation in RBL-2H3 cells stimulated with 10, 50 or 250 ng/ml DNP-HSA, with maximal inhibition occurring at 5-20 ng/10⁶ RBL-2H3 cells. RBL-2H3 cells were saturated

-33-

with DNP-specific IgE and labeled with ³H-hydroxytryptamine (serotonin) 0.2 mCi/10⁶ cells/well (0.32 cm), washed three times with triggering buffer and incubated for 30 minutes at room temperature with the indicated concentration of affinity-purified 5D1 mAb in 25 ml total volume. After incubation, cells were challenged with 25 μ l of 2X dilution of pre-warmed DNP-HSA and triggered for 30 minutes (37°C, 5% CO₂). Release was terminated by the addition of 150 μ l of ice-cold triggering buffer and by placing the plates on ice. 100 μ l aliquots of released radioactivity as well as SDS cell lysates were then harvested and scintillation counted. Degranulation-inhibitory mAb binding has little or no effect on IgE or anti-Fc ϵ R1 α binding.

-39-

TABLE 1: Binding inhibition of FITC-conjugated mAbs directed to RBL-2H3 surface antigens

		Median Fluorescence Intensity (MFI)			
		<u>FITC-conjugated mAbs</u>			
5	<u>Preincubation</u> <u>Specificity</u>	<u>1A12</u>	<u>IgE</u>	<u>4H7</u>	<u>3A9</u>
	-	37.9	75.0	83.5	289.0
	1A12	ND	61.0	83.5	289.0
	5D1	6.5	ND	ND	ND
	4H7	38.2	6.4	7.2	33.5
10	3A9	37.5	6.5	6.8	13.4
	BC4	38.5	5.8	5.4	5.9
	5.14	39.6	5.5	84.3	161.0
	AA4	ND	12.3	59.3	201.7

G_{01b}

- 15 10⁶ RBL-2H3 cells were incubated on ice with a saturating amount of unconjugated antibody (preincubation) for 30 minutes prior to the addition (without washes) of a titrated (subsaturating) concentration of FITC-conjugated mAb. After washes, stained cells were analyzed by FACS and mean
- 20 values histogram peaks converted to median fluorescent intensity (MFI) units.

EQUIVALENTS

- While this invention has been particularly shown and described with references to preferred embodiments thereof,
- 25 it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the following claims. Those skilled in the art will recognize or be able to ascertain
- 30 using no more than routine experimentation, many equivalents to the specific embodiments of the invention

-40-

described specifically herein. Such equivalents are intended to be encompassed in the scope of the claims.

-41-

CLAIMS

We claim:

1. A calcium independent method of inhibiting cell surface receptor-mediated signaling comprising
5 contacting a cell with an agent which induces CD81-mediated signal transduction.
2. A method according to Claim 1, wherein the cell surface receptor is selected from the group consisting of FcεRI and FcγRIII.
- 10 3. A calcium-independent method of inhibiting degranulation comprising contacting a cell with an agent which induces CD81-mediated signal transduction.
4. A method according to Claim 3, wherein the degranulation is mediated by the FcεRI receptor.
- 15 5. A calcium independent method of inhibiting cell surface receptor-mediated signaling in a mammal comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction.
- 20 6. A method according to Claim 5, wherein the cell surface receptor is selected from the group consisting of FcεRI and FcγRIII.
7. A calcium independent method of inhibiting degranulation induced by a cell surface receptor-mediated signal in a mammal comprising administering
25 to the mammal an effective amount of an agent which induces CD81-mediated signal transduction.

-42-

8. A method of treating an allergic condition in a mammal comprising administering to the mammal an effective amount of an agent which induces CD81-mediated signal transduction.
- 5 9. A method according to Claim 8, wherein the allergic condition is asthma, hay fever or atopic eczema.
10. A calcium independent method of enhancing cell surface receptor-mediated signaling comprising contacting a cell with an agent which inhibits CD81-mediated signal
10 transduction.
11. A method according to Claim 10, wherein the cell surface receptor is selected from the group consisting of FcεRI and FcγRIII.
12. A calcium independent method of enhancing
15 degranulation comprising contacting a cell with an agent which inhibits CD81-mediated signal transduction.
13. A method according to Claim 12, wherein the degranulation is mediated by the FcεRI receptor.
- 20 14. A calcium independent method of enhancing cell surface receptor-mediated signaling in a mammal comprising administering to the mammal an effective amount of an agent which inhibits CD81-mediated signal transduction.
- 25 15. A method according to Claim 14, wherein the cell surface receptor is selected from the group consisting of FcεRI and FcγRIII.

-43-

16. An assay for identifying agents which alter CD81 mediated signal transduction, comprising the steps of:
- a) combining a cell bearing CD81 with an agent to be tested under conditions suitable for CD81-mediated signal transduction; and
 - b) determining the level of CD81-mediated signal transduction,

wherein if the level of CD81-mediated signal transduction is altered relative to a control, the agent alters CD81-mediated signal transduction.

17. An assay for identifying agents which alter calcium independent CD81-mediated regulation of cell surface receptor signaling, comprising the steps of:

- a) combining a cell bearing CD81 and an appropriate cell surface receptor with an agent which alters CD81-mediated signal transduction under conditions suitable for signal transduction by CD81 and the cell surface receptor; and
- b) determining the level of cell surface receptor signaling;

wherein if the level of cell surface receptor signaling is altered relative to a control, the agent alters calcium independent CD81-mediated regulation of cell surface receptor signaling.

18. A method according to Claim 17, wherein the cell surface receptor is selected from the group consisting of FcεRI and FcγRIII.

19. A method of inhibiting passive cutaneous anaphylaxis in a mammal comprising administering to the mammal an effective amount of an agent which enhances CD81-mediated signal transduction.

-44-

20. A method according to Claim 19, wherein the agent is an anti-CD81 monoclonal antibody.

FIG. 1A




FIG. 1B





FIG. 1C



2/13




FIG. 2

3/13




FIG. 3

SUBSTITUTE SHEET (RULE 26)

4/13




FIG. 4

Rat CD81-1A12	FYDQALQQAVMXDD
	D D D
Mouse CD81	FYDQALQQAVMDDD
Human CD81	FYDQALQQAVVDDD

FIG. 5




FIG. 6B




FIG. 6A

7/13




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 7D

Expression of rat CD81 in mouse C1.MC/C57.1 cells




FIG. 8

9/13




FIG. 9A




FIG. 9B





FIG. 9C

10/13


FIG. 10A



Coinjections:

t-24h	{	anti-DNP IgE (ng)	25	25	0	0	0
		MOPC 31c IgG1 (µg)	50	0	50	0	0
		anti-CD81 (µg)	0	50	0	50	0

FIG. 10B

Separate injections:

t-24h	{	anti-DNP IgE (ng)	100	100	100	0	0	0
		anti-LFA-1 (µg)	0	50	0	50	0	0
t-3h	{	anti-CD81 (µg)	0	0	50	0	50	0

11/13




FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D

12/13




FIG. 12A




FIG. 12B

13/13




FIG. 12C




FIG. 12D

INTERNATIONAL SEARCH REPORT

National Application No.

PCT/US 97/22743

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K39/395 G01N33/53 G01N33/68 //C07K14/705, C07K16/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	M. ANDRIA ET AL.: "Genomic organization and chromosomal localization of the TAPA-1 gene." THE JOURNAL OF IMMUNOLOGY, vol. 147, no. 3, 1991, BALTIMORE, MD, USA, pages 1030-1036, XP002064247 see abstract see figures 2,3 ---	1-20
A	S. LEVY ET AL.: "Structure and membrane topology of TAPA-1." THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 22, 5 August 1991, BALTIMORE, MD, USA, pages 14597-14602, XP002064248 see figures 1,7 see page 14602, left-hand column, line 32 - line 38 --- -/--	1-20

☒ Further documents are listed in the continuation of box C.☐ Patent family members are listed in annex

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

Z document member of the same patent family

Date of the actual completion of the international search

7 May 1998

Date of mailing of the international search report

28. 05. 1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Nooij, F

INTERNATIONAL SEARCH REPORT

international application No
PCT/US 97/22743

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons

1. ☒ Claims Nos. :
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos. :
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos. :
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US 97/22743

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Remark : Although claims 1-4 and 10-13 (all partially, as far as an in vivo method is concerned) and claims 5-9, 14, 15, 19 and 20 (all completely) are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/22743

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
A	M. BENHAMOU ET AL.: "Protein tyrosine kinases in activation signal of human basophils through the immunoglobulin E receptor type 1." JOURNAL OF LEUKOCYTE BIOLOGY, vol. 59, no. 3, March 1996, NEW YORK, NY, USA, pages 461-470, XP002064249 see abstract see discussion	1-20
P,X	--- T. FLEMING ET AL.: "Negative regulation of Fc epsilon RI-mediated degranulation by CD81." THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 20 October 1997, NEW YORK, NY, USA, pages 1307-1314, XP002064250 see the whole document -----	1-9, 16-20